



**HTA Austria**  
Austrian Institute for  
Health Technology Assessment  
GmbH

## Covid-19 APPENDIX

---

HSS/ Horizon Scanning  
Living Document Update July 2020



**HTA Austria**  
Austrian Institute for  
Health Technology Assessment  
GmbH

## Covid-19 APPENDIX

---

HSS/ Horizon Scanning  
Living Document Update July 2020

**Projektteam**

Projektleitung: PD Dr. Claudia Wild

**Projektbearbeitung:**

Extraktion-, Kontroll- und Formatierarbeiten: Ozren Sehic, BA; Smiljana Blagojevic, Dipl.-Ing.

**Korrespondenz:** Claudia Wild, [claudia.wild@aihta.at](mailto:claudia.wild@aihta.at)

**Dieser Bericht soll folgendermaßen zitiert werden/This report should be referenced as follows:**

AIHTA Policy Brief Nr.: 002, Appendix; 2020. Covid-19, HSS/ Horizon Scanning, Living Document July 2020, Part 2. Wien: HTA Austria – Austrian Institute for Health Technology Assessment GmbH.

**Interessenskonflikt**

Alle beteiligten AutorInnen erklären, dass keine Interessenskonflikte im Sinne der Uniform Requirements of Manuscripts Statement of Medical Journal Editors ([www.icmje.org](http://www.icmje.org)) bestehen.

**IMPRESSUM****Medieninhaber und Herausgeber:**

**HTA Austria** - Austrian Institute for Health Technology Assessment GmbH  
Garnisongasse 7/Top20 | 1090 Wien – Österreich  
[www.aihta.ac.at](http://www.aihta.ac.at)

**Für den Inhalt verantwortlich:**

Priv.-Doz. Dr. phil. Claudia Wild, Geschäftsführung

Die **AIHTA Policy Briefs** erscheinen unregelmäßig und dienen der Veröffentlichung der Forschungsergebnisse des Austrian Institute for Health Technology Assessment.

Die **AIHTA Policy Briefs** erscheinen in geringer Auflage im Druck und werden über den Dokumentenserver „<https://eprints.aihta.at/view/types/policy=5Fbrief.html>“ der Öffentlichkeit zur Verfügung gestellt.

AIHTA Policy Brief Nr.: 002

ISSN 2710-3234

ISSN online 2710-3242

© 2020 AIHTA – Alle Rechte vorbehalten

# Inhalt

Inhalt ..... 3

Appendix 1 Vaccines (n=180)..... 5

Appendix 2 Therapeutics (n=319) ..... 16

Appendix 3 EudraCT registered studies (n=29) ..... 30

**Tabellenverzeichnis**

Table A 1: Covid19 vaccines in development (all).....5

Table A 2: Covid19 medicines in development (all).....16

Table A 3: EudraCT registered Covid19 studies (all).....30



## Appendix 1 Vaccines (n=180, July 1<sup>st</sup> 2020), source: COVID-19 R&D Tracker, <https://www.policycuresresearch.org/covid-19-r-d-tracker>

Table A 1: Covid19 vaccines in development (all)

Candidate Name	Developer	Innovation Type	Platform/Technology		R&D Stage
BCG vaccine	Melbourne Children's Campus (including the Global Health initiative, Murdoch Children's Research Institute, Royal Children's Hospital and the University of Melbourne's Paediatrics Department) Utrecht University (including University Medical Center Utrecht) University Medical Center St Radboud	Preventive	Live attenuated strain of Mycobacterium bovis (BCG)		Phase III
VPM1002	Vakzine Projekt Management GmbH	Preventive	Live attenuated strain of Mycobacterium bovis (BCG)		Phase III
AZD1222 (ChAdOx1 nCoV-19)	University of Oxford AstraZeneca Serum Institute of India (SII) Vaccitech Limited	Preventive	Non-replicating viral vector	ChAdOx1	Phase II/III
Ad5-nCoV	Tianjin CanSino Biotechnology Inc. (CanSino) Beijing Institute of Technology (BIT) Jiangsu Province Centers for Disease Control and Prevention Hubei Provincial Center for Disease Control and Prevention	Preventive	Non-replicating viral vector		Phase II
mRNA-1273	Moderna Therapeutics (including Valera) US National Institute of Allergy and Infectious Disease (NIAID)	Preventive	RNA	LNP-encapsulated mRNA	Phase II
AV-COVID-19	Aivita Biomedical Inc	Preventive	Dendritic cell		Phase I/II
BBIBP-CorV	CNBG - Beijing	Preventive	Inactivated		Phase I/II
BNT162 mRNA vaccine	BioNTech Fosun Pharma Pfizer	Preventive	RNA	mRNA	Phase I/II
Coronavac	Sinovac Biotech Ltd	Preventive	Inactivated	Inactivated + alum	Phase I/II

Inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)	CNBG - Wuhan	Preventive	Inactivated		Phase I/II
Inactivated SARS-CoV-2 Vaccine	Institute of Medical Biology Chinese Academy of Medical Sciences	Preventive	Inactivated		Phase I/II
INO-4800 DNA vaccine	Inovio Pharmaceuticals, Inc. Ology Bioservices IVI Korea National Institute of Health (KNIH)	Preventive	DNA	DNA plasmid vaccine Electroporation device	Phase I/II
LV-SARS-CoV-2-aAPC vaccine	Shenzhen Geno-Immune Medical Institute Shenzhen Third People's Hospital Shenzhen Second People's Hospital	Preventive	Non-replicating viral vector		Phase I/II
LV-SMENP-DC vaccine and antigen-specific CTLs	Shenzhen Geno-Immune Medical Institute Shenzhen Third People's Hospital Shenzhen Second People's Hospital	Preventive	Non-replicating viral vector		Phase I/II
ARCoV	PLA Academy of Military Sciences Walvax Biotechnology	Preventive	RNA		Phase I
bacTRL-Spike	Symvivo Corporation	Preventive	Other		Phase I
Gam-COVID-Vac Lyo	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	Preventive	Non-replicating viral vector		Phase I
LNP-nCoVsaRNA	Imperial College London	Preventive	RNA	saRNA	Phase I
NVX-CoV2373 +/- Matrix-M Adjuvant	Novavax Emergent Biosolutions (including Microscience, Antex biologicals Inc, Emergent Product Development and Unither)	Preventive	Protein subunit	VLP-recombinant protein nanoparticle vaccine + Matrix M	Phase I
SARS-CoV-2 mRNA vaccine	CureVac GmbH	Preventive	RNA	mRNA	Phase I
SCB-2019 +/- AS03/ CpG 1018	GSK Bio Dynavax Technologies Corporation Clover Biopharmaceuticals Inc.	Preventive	Protein subunit	Native like Trimeric subunit Spike Protein vaccine	Phase I
Unknown	Ange's Inc Osaka University	Preventive	DNA		Phase I
Liposome-encapsulated mRNA COVID vaccine	BiOCAD	Preventive	RNA		Pre-clinical
1c-SAPNP platform-based vaccine	Ufovax	Preventive	Virus-like particles		Pre-clinical
AADvac1	Axon Neuroscience	Preventive	Protein subunit		Pre-clinical

AAVCOVID	Massachusetts Eye and Ear Massachusetts General Hospital Perelman School of Medicine at the University of Pennsylvania AveXis	Preventive	Non-replicating viral vector		Pre-clinical
Ad26 SARS-CoV-2	Johnson & Johnson Beth Israel Deaconess Medical Center	Preventive	Non-replicating viral vector		Pre-clinical
Ad5 adenovirus-based vaccine	ImmunityBi NantKwest, Inc.	Preventive	Non-replicating viral vector		Pre-clinical
AdCOVID	Altimune Inc University of Alabama at Birmingham	Preventive	Non-replicating viral vector	Adenovirus-based NasoVAX expressing SARS2- CoV spike protein	Pre-clinical
ADDomer COVID-19 vaccine	Imophoron Ltd Max Planck Centre, Bristol University	Preventive	Virus-like particles	ADDomer™ multiepitope display	Pre-clinical
Adenovirus-based vector vaccine for COVID-19	Greffex	Preventive	Non-replicating viral vector	Ad5 S (GREVAX™ platform)	Pre-clinical
Adenoviruses encoded SARS- CoV-2 coated with MHC-I - restricted peptide	ReiThera Srl University of Helsinki VALO therapeutics	Preventive	Non-replicating viral vector		Pre-clinical
Adenovirus-vectored vaccine	Tsinghua University	Preventive	Non-replicating viral vector		Pre-clinical
Adjuvanted protein subunit (RBD) COVID vaccine	Biological E Ltd	Preventive	Protein subunit	Adjuvanted protein subunit (RBD)	Pre-clinical
AVI-205	AbVision	Preventive	Active targeting vaccine		Pre-clinical
CD8+ priming RNA virus vaccine	Emergex George Mason University	Preventive	RNA		Pre-clinical
CDX-CoV	Codagenix, Inc. Serum Institute of India (SII)	Preventive	Live attenuated virus	Deoptimized live attenuated vaccines	Pre-clinical
Codon de-optimised Live Attenuated COVID-19	Indian Immunologicals Limited Griffith University	Preventive	Live attenuated virus		Pre-clinical
CORAVAX™	Thomas Jefferson University	Preventive	Non-replicating viral vector		Pre-clinical
CoroFlu	University of Wisconsin–Madison FluGen Bharat Biotech	Preventive	Non-replicating viral vector		Pre-clinical
CORVax12	OncoSec Providence Cancer Institute UbiVac TriAltus Bioscience	Preventive	DNA		Pre-clinical



COVID-19 XWG-03 truncated S (spike) protein + Adjuvant vaccine	Innovax Xiamen University GSK	Preventive	Protein subunit	COVID-19 XWG-03 truncated S (spike) proteins	Pre-clinical
COVIDITY	Scancell Nottingham Trent University University of Nottingham	Preventive	DNA		Pre-clinical
COVIGEN	Bionet-Asia Co., Ltd.	Preventive	DNA		Pre-clinical
CuMVtt platform-based VLP vaccine	Saiba GmbH	Preventive	Virus-like particles		Pre-clinical
DeINS1-SARS-CoV2-RBD LAIV	University of Hong Kong (including the University of Hong Kong Clinical Trials Centre, HKU-CTC)	Preventive	Replicating viral vector	Influenza vector expressing RBD	Pre-clinical
Dendritic cell-based vaccine	University of Manitoba	Preventive	Non-replicating viral vector		Pre-clinical
Deoptimized live attenuated SARS-CoV-2	Codagenix, Inc. Serum Institute of India (SII)	Preventive	Live attenuated virus	Deoptimized live attenuated vaccines	Pre-clinical
DNA-based vaccine for COVID-19	Takis Applied DNA Sciences/Evvivax	Preventive	DNA	DNA	Pre-clinical
DPX-COVID-19	IMV Inc.	Preventive	Protein subunit		Pre-clinical
EPV-CoV-19	EpiVax	Preventive	Protein subunit		Pre-clinical
Esco Aster DeltaCov	Vivaldi Biosciences Esco Aster	Preventive	Non-replicating viral vector		Pre-clinical
Exosome-SARS-CoV-2 Display vaccine	Capricor Therapeutics Johns Hopkins University	Preventive	Protein subunit		Pre-clinical
Exosome-SARS-CoV-2 mRNA vaccine	Capricor Therapeutics Johns Hopkins University	Preventive	RNA		Pre-clinical
FlowVax COVID-19	Flow Pharma Inc	Preventive	Protein Subunit	Peptide	Pre-clinical
Fusogenix DNA vaccine	Entos Pharmaceuticals	Preventive	DNA		Pre-clinical
Gene MAb <sup>TM</sup> for Coronavirus	Sorrento Therapeutics Inc.	Preventive	DNA		Pre-clinical
gp96-based vaccine	Heat Biologics (including Zolovax) University of Miami (including the Miller School of Medicine)	Preventive	Protein subunit	gp-96 backbone	Pre-clinical
GV-MVA-VLP	GeoVax Labs, Inc. BravoVax	Preventive	Non-replicating viral vector		Pre-clinical
GX-19 DNA vaccine	Genexine International Vaccine Institute (IVI) Binex	Preventive	DNA		Pre-clinical
IBIO-200	iBio, Inc Beijing CC-Pharming Ltd Texas A&M University	Preventive	Protein subunit	Subunit protein, plant produced	Pre-clinical
Ii-Key-SARS-CoV-2 peptide vaccine	Generex EpiVax	Preventive	Protein subunit		Pre-clinical

IMT504	Nidovax	Preventive	Unknown		Pre-clinical
Inactivated (inactivated + CpG 1018)	Sinovac/ Dynavax	Preventive	Inactivated		Pre-clinical
Inactivated COVID vaccine	Research Foundation for Microbial Diseases of Osaka University (BIKEN) National Institutes of Biomedical Innovation, Health, and Nutrition (NIBIOHN)	Preventive	Inactivated	TBD	Pre-clinical
Intranasal viral vectored COVID vaccine	BiCAD IEM	Preventive	Replicating viral vector		Pre-clinical
Linear DNA vaccine	Linearx Inc.; Takis Biotech	Preventive	DNA		Pre-clinical
LNP-encapsulated mRNA COVID vaccine	University of Tokyo Daiichi-Sankyo	Preventive	RNA	LNP- encapsulated mRNA	Pre-clinical
LUNAR-COV19	Arcturus Duke-NUS	Preventive	RNA	mRNA	Pre-clinical
measles vector	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	Preventive	Replicating viral vector		Pre-clinical
Modified avian coronavirus vaccine	MIGAL Galilee Research	Preventive	Protein subunit		Pre-clinical
mRNA	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	Preventive	RNA		Pre-clinical
mRNA lipid nanoparticle (mRNA-LNP)	CanSino Biologics Precision Nanosystems	Preventive	RNA		Pre-clinical
mRNA vaccine	Sanofi Pasteur Translate Bio	Preventive	RNA	MRNA	Pre-clinical
mRNA vaccine candidate for COVID-19	Fudan University Shanghai JiaoTong University RNACure Biopharma	Preventive	RNA	LNP-encapsulated mRNA cocktail encoding VLP	Pre-clinical
MV-014-210	Meissa Vaccines	Preventive	Live attenuated virus		Pre-clinical
MVA expressing structural protein COVID vaccine	Centro Nacional Biotecnología (CNB-CSIC), Spain	Preventive	Non-replicating viral vector		Pre-clinical
Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)	Intravacc Wageningen Bioveterinary Research Utrecht Univ.	Preventive	Replicating viral vector		Pre-clinical
oligoDOM® platform-based vaccine	OSIVAX	Preventive	Virus-like particles		Pre-clinical
OMV-based vaccine	Quadram Institute Biosciences	Preventive	Protein subunit		Pre-clinical
Oral recombinant vaccine based on VAAST™ platform	Vaxart Emergent BioSolutions Inc.	Preventive	Non-replicating viral vector	Oral Vaccine platform	Pre-clinical
Outer Membrane Vesicle (OMV)-peptide	Intravacc Epivax	Preventive	Protein subunit		Pre-clinical

parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein	University of Georgia University of Iowa	Preventive	Non-replicating viral vector		Pre-clinical
PDS0203	PDS Biotechnology	Preventive	Protein subunit		Pre-clinical
peptide vaccine	FBRI SRC VB VECTOR Rospotrebnadzor, Koltsovo	Preventive	Protein subunit		Pre-clinical
PittCoVacc	University of Pittsburgh	Preventive	Protein subunit	microneedle arrays S1 subunit	Pre-clinical
Plant virus nanotechnology formulated as injectable and microneedle patch	University of California, San Diego	Preventive	Protein subunit		Pre-clinical
Plant-based vaccine	G+Flas Life Sciences	Preventive	Protein subunit		Pre-clinical
Protein subunit vaccine	Sanofi Pasteur	Preventive	Protein subunit	S protein (baculovirus production)	Pre-clinical
Protein subunit vaccine (molecular clamp)	The University of Queensland GSK bio Dynavax Technologies Corporation CSIRO Australian Animal Health Laboratory	Preventive	Protein subunit	Molecular clamp stabilized Spike protein	Pre-clinical
RBD-based	Neovii Tel Aviv University	Preventive	Protein subunit		Pre-clinical
Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens	University of California, Los Angeles (Horwitz Lab)	Preventive	Replicating listeria vector		Pre-clinical
Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	Preventive	Replicating viral vector		Pre-clinical
Replicating viral vector; VSV-S	University of Western Ontario	Preventive	Replicating viral vector		Pre-clinical
Replication defective RNA vaccine	Centro Nacional Biotecnología (CNB-CSIC), Spain	Preventive	RNA		Pre-clinical
rOMV vaccine	Versatope Umass	Preventive	Protein subunit		Pre-clinical
S protein + Adjuvant COVID vaccine	National Institute of Infectious Disease, Japan	Preventive	Protein subunit	S protein+Adjuvant	Pre-clinical
S protein vaccine	Walter Reed Army Institute of Research (WRAIR) (including Military HIV Research Program (MHRP))	Preventive	Protein subunit		Pre-clinical

	US Army Medical Research Institute of Infectious Diseases (USAMRIID)				
SARS-CoV-2 measles vector vaccine	Institute Pasteur Themis Bioscience GmbH University of Pittsburgh	Preventive	Replicating viral vector	Measles Vector	Pre-clinical
SARS-CoV-2 membrane protein Plasmid DNA vaccine	Zydus Cadila (including Cadila Healthcare)	Preventive	DNA	DNA plasmid vaccine	Pre-clinical
SARS-CoV-2 recombinant measles virus (rMV)	Zydus Cadila (including Cadila Healthcare)	Preventive	Replicating viral vector	Measles Vector	Pre-clinical
SARS-CoV-2 vaccine	Chongqing Zhifei Biological Products Co. Ltd.; Institute of Microbiology, Chinese Academy of Sciences	Preventive	Protein subunit		Pre-clinical
SARS-CoV-2 VLP	Medicago USA Laval University	Preventive	Virus-like particles	Plant-derived VLP	Pre-clinical
Self-assembling vaccine (SAV) platform-based vaccine	Hoth Therapeutics HaloVax, LLC Massachusetts General Hospital	Preventive	Self-assembling vaccine (SAV)		Pre-clinical
STI-6991	Sorrento Therapeutics Inc. Rutgers New Jersey Medical School	Preventive	Non-replicating viral vector		Pre-clinical
subunit vaccine	FBRI SRC VB VECTOR Rospotrebnadzor, Koltsovo	Preventive	Protein subunit		Pre-clinical
Synthetic Peptide Mini-Scaffold Vaccines	Ligandal, Inc.	Preventive	Peptide		Pre-clinical
TerraCoV2	Orogenics (Noachis Terra) Aragen Bioscience	Preventive	Protein subunit		Pre-clinical
TNX-1800	Tonix Pharma Southern Research	Preventive	Replicating viral vector	Horsepox vector expressing S protein	Pre-clinical
TNX-1810	University of Alberta	Preventive	Protein subunit		Pre-clinical
TNX-1820	University of Alberta Tonix Pharmaceuticals	Preventive	Protein subunit		Pre-clinical
TNX-1830	University of Alberta Tonix Pharmaceuticals	Preventive	Protein subunit		Pre-clinical
UNITETM platform-based needle free COVID vaccine	Immunomic Therapeutics, Inc. EpiVax PharmaJet, Inc.	Preventive	DNA		Pre-clinical
Unknown	AJ Vaccines	Preventive	Protein subunit	S protein	Pre-clinical

Unknown	Baylor College of Medicine at Texas Children's Hospital (including Baylor International Pediatric AIDS Initiative (BIPAI))	Preventive	Protein subunit	S1 or RBD protein	Pre-clinical
Unknown	CEL-SCI	Preventive	Protein subunit		Pre-clinical
Unknown	China CDC Tongji University Stermina	Preventive	RNA		Pre-clinical
Unknown	EpiVax University of Georgia (UGA)	Preventive	Protein subunit	S protein	Pre-clinical
Unknown	ExpreS2ion Biotechnologies AdaptVac Leiden University Medical Center (LUMC) Institute for Tropical Medicine (ITM) at University of Tübingen University of Copenhagen Wageningen University	Preventive	Protein subunit		Pre-clinical
Unknown	German Centre for Infection Research (Deutschen Zentrums für Infektionsforschung) (DZIF)	Preventive	Live attenuated virus	Measles Virus (S, N targets)	Pre-clinical
Unknown	German Centre for Infection Research (Deutschen Zentrums für Infektionsforschung) (DZIF)	Preventive	Non-replicating viral vector	MVA-S encoded	Pre-clinical
Unknown	Immune System Regulation (ISR)	Preventive	Protein subunit		Pre-clinical
Unknown	International AIDS Vaccine Initiative (IAVI) Batavia Biosciences	Preventive	Replicating viral vector	VSV vector expressing S protein	Pre-clinical
Unknown	Karolinska Institute, Karolinska Institutet Cobra Biologics	Preventive	DNA		Pre-clinical
Unknown	Medicago USA	Preventive	Protein subunit		Pre-clinical
Unknown	Medigen	Preventive	Protein subunit		Pre-clinical
Unknown	OncoGen	Preventive	Protein subunit	Synthetic Long Peptide Vaccine candidate for S and M proteins	Pre-clinical
Unknown	Saiba GmbH	Preventive	Protein subunit		Pre-clinical
Unknown	Saint-Petersburg Scientific Research Institute of Vaccines and Serums	Preventive	Protein subunit	Recombinant protein, nanoparticles (based on S- protein and other epitopes)	Pre-clinical
Unknown	SK Chemicals	Preventive	Protein subunit		Pre-clinical

Unknown	Soligenix Inc. University of Hawaii at Manoa	Preventive	Protein subunit		Pre-clinical
Unknown	Stabilitech Biopharma Ltd.	Preventive	Non-replicating viral vector		Pre-clinical
Unknown	Sumagen Co. Ltd. International Vaccine Institute (IVI)	Preventive	Replicating viral vector		Pre-clinical
Unknown	Thomas Jefferson University	Preventive	Protein subunit		Pre-clinical
Unknown	UMN Pharma	Preventive	Protein subunit		Pre-clinical
Unknown	Vaxil Bio	Preventive	Protein subunit	Peptide	Pre-clinical
Unknown	VIDO-InterVac, University of Saskatchewan	Preventive	Protein subunit	Subunit	Pre-clinical
Unnamed	British American Tobacco	Preventive	Protein subunit		Pre-clinical
Unnamed	Chimeron Bio George Mason University	Preventive	RNA		Pre-clinical
Unnamed	DIOSynVax University of Cambridge	Preventive	Protein subunit		Pre-clinical
Unnamed	GeneOne Life Science Houston Methodist	Preventive	RNA		Pre-clinical
Unnamed	Greenlight Biosciences	Preventive	RNA		Pre-clinical
Unnamed	Helix Biogen Consult Elizade University Massasoit Community College Ladoke Akintola University	Preventive	Unknown		Pre-clinical
Unnamed	IrsiCaixa AIDS Research IRTA-CReSA Barcelona Supercomputing Centre Grifols	Preventive	Virus-like particles		Pre-clinical
Unnamed	Israel Institute for Biological Research Weizmann Institute of Science	Preventive	Replicating viral vector		Pre-clinical
Unnamed	LakePharma, Inc.	Preventive	Protein subunit		Pre-clinical
Unnamed	Massachusetts Institute of Technology	Preventive	Protein subunit		Pre-clinical
Unnamed	Research Institute for Biological Safety Problems Republic of Kazakhstan	Preventive	Inactivated		Pre-clinical
Unnamed	Sichuan University Zhejiang Teres Pharmaceutical Chengdu National GLP Center Sichuan Provincial People's Chengdu Institute of Biological ProductsHospital	Preventive	Protein subunit		Pre-clinical
Unnamed	SK Biosciences	Preventive	Protein subunit		Pre-clinical
Unnamed	University of Alberta	Preventive	Protein subunit		Pre-clinical

Unnamed	University of Waterloo	Preventive	DNA		Pre-clinical
Unnamed	Vabiotech	Preventive	Protein subunit		Pre-clinical
Unnamed	Vaxine Pty Ltd Flinders University Oracle	Preventive	Protein subunit		Pre-clinical
Unnamed	Verndari Inc UC Davis	Preventive	Protein subunit		Pre-clinical
Unnamed	Vivaldi Biosciences Esco Aster	Preventive	Unknown		Pre-clinical
Unnamed	Western University	Preventive	Replicating viral vector		Pre-clinical
Unnamed mRNA vaccine	eTheRNA Immunotherapies TriMix EpiVax Nexelis REPROCELL University of Antwerp	Preventive	RNA		Pre-clinical
Vault-based vaccine	Vault Pharma University of California Los Angeles	Preventive	Protein subunit		Pre-clinical
Vaxcelerate vaccine	Hoth Therapeutics Inc.; Voltron Therapeutics Inc.	Preventive	Protein subunit		Pre-clinical
VBI-2901	National Research Council of Canada VBI Vaccines	Preventive	Protein subunit		Pre-clinical
VBI-2901 Pan-Coronavirus Vaccine	VBI Vaccines National Research Council of Canada (NRC)	Preventive	Virus-like particles		Pre-clinical
VLA 2001	Dynavax Technologies Corporation Valneva	Preventive	Inactivated		Pre-clinical
VLP; eVLP	ARTES Biotechnology	Preventive	Virus-like particles		Pre-clinical
VLP-recombinant protein + Adjuvant COVID vaccine	Research Foundation for Microbial Diseases of Osaka University (BIKEN) National Institutes of Biomedical Innovation, Health, and Nutrition (NIBIOHN)	Preventive	Protein subunit	VLP-recombinant protein + Adjuvant	Pre-clinical
VLPs peptides/whole virus	Immunology Laboratory of the Heart Institute (INCOR), University of São Paulo's Medical School (FM-USP)	Preventive	Virus-like particles		Pre-clinical
VSV vector	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	Preventive	Replicating viral vector		Pre-clinical
YF17D Vector	KU Leuven	Preventive	Replicating viral vector		Pre-clinical
ZIP-1642	Ziphius Therapeutics NV	Preventive	RNA		Pre-clinical
exoVACC™	Codiak BioSciences Ragon Institute	Preventive	Engineered exosomes		Discovery

Gliovac/ERC1671 glioblastoma platform-based vaccine	Epitopoietic Research Corporation	Preventive	Virions		Discovery
Ministring DNA vaccine	Mediphage Biocuticals, Inc	Preventive	DNA		Discovery
Peptide carrier fusion vaccines (PCFiT)-based vaccine	Viravaxx AG Medical University of Vienna	Preventive	Protein subunit		Discovery
Unnamed	Akers Biosciences, Inc. Premas Biotech	Preventive	Protein subunit		Discovery
Unnamed	City of Hope	Preventive	DNA		Discovery
Unnamed	INNOMEDICA HOLDING AG	Preventive	Protein subunit		Discovery
Unnamed	Mynvax Indian Institute of Science (IISc)	Preventive	Protein subunit		Discovery
Unnamed	Oregon Health & Science University PDX Pharmaceuticals, Inc.	Preventive	Protein subunit		Discovery
Unnamed	PT Bio Farma Eijkman Molecular Biology Institute	Preventive	Protein subunit		Discovery
Z-VacciRNA	Guanhao Biotech Co. Ltd.; Zy Therapeutics Inc.	Preventive	RNA		Discovery



## Appendix 2 Therapeutics (n=319, July 1st 2020), source: COVID-19 R&D Tracker, <https://www.policycuresresearch.org/covid-19-r-d-tracker>

Table A 2: Covid19 medicines in development (all)

Candidate Name	Developer	Innovation Type	Platform/Technology	R&D Stage
Adalimumab	Shanghai Changzheng Hospital	Repurposed drug	Anti-inflammatory / immunomodulator	Phase IV
Adalimumab + Tozumab	Shanghai General Hospital	Repurposed drug	Anti-inflammatory / immunomodulator	Phase IV
Arbidol (Umifenovir)	Multiple trials	Repurposed drug	Anti-virals	Phase IV
Arbidol + Recombinant Human Interferon α2b Spray	Tongji Hospital	Repurposed drug	Anti-virals	Phase IV
chloroquine phosphate plus Lopinavir/ritonavir	The Fifth Affiliated Hospital of Sun Yat-Sen University	Repurposed drug	Anti-virals	Phase IV
Colchicine	National and Kapodistrian University of Athens	Repurposed drug	Anti-inflammatory / immunomodulator	Phase IV
Danoprevir+ritonavir+/-Interferon nebulization	Asclepis Pharmaceuticals Co., Ltd. The Ninth Hospital of Nanchang	Repurposed drug	Anti-virals	Phase IV
Favipiravir and tocilizumab	Peking University First Hospital	Repurposed drug	Anti-virals	Phase IV
HCQ + Camostat	Heinrich-Heine University, Duesseldorf	Repurposed drug	Anti-virals	Phase IV
Hydroxychloroquine + lopinavir/ritonavir	Berry Consultants Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health	Repurposed drug	Anti-virals	Phase IV
Novaferon + lopinavir / ritonavir	Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd The First Hospital of Changsha The Second Xiangya Hospital of Central South University	Repurposed drug	Anti-virals	Phase IV
Oseltamivir	Tongji Hospital	Repurposed drug	Anti-virals	Phase IV
Sargramostim	University Hospital, Ghent Flanders Institute of Biotechnology	Repurposed drug	Anti-inflammatory / immunomodulator	Phase IV
ASC09F+Oseltamivir	Tongji Hospital	Repurposed drug	Anti-virals	Phase III
Azithromycin	Pfizer Inc. University of California, San Francisco	Repurposed drug	Anti-virals	Phase III
CD24Fc	Oncolmmune, Inc., University of Maryland Baltimore	Anti-inflammatory / immunomodulator	Novel	Phase III
Dapagliflozin (Farxiga)	AstraZeneca Saint Luke's Health System George Clinical Pty Ltd	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Darunavir	Rajavithi Hospital	Repurposed drug	Anti-virals	Phase III

Darunavir /ritonavir favipiravir chloroquine	Rajavithi Hospital	Repurposed drug	Anti-virals	Phase III
Darunavir /ritonavir oseltamivir chloroquine	Rajavithi Hospital	Repurposed drug	Anti-virals	Phase III
Darunavir and Ritonavir plus oseltamivir	Rajavithi Hospital	Repurposed drug	Anti-virals	Phase III
Darunavir/cobicistat	Shanghai Public Health Clinical Center Hongzhou Lu, Shanghai Public Health Clinical Center	Repurposed drug	Anti-virals	Phase III
DAS181	Ansun Biopharma, Inc.	Novel	Anti-virals	Phase III
Emtricitabine/tenofovir disoproxil	Plan Nacional sobre el Sida (PNS) Effice Servicios Para la Investigacion S.L.	Repurposed drug	Anti-virals	Phase III
Emtricitabine/Tenofovir+Hydroxychloroquine	Plan Nacional sobre el Sida (PNS) Effice Servicios Para la Investigacion S.L.	Repurposed drug	Anti-virals	Phase III
Favipiravir (or T-705 or Avigan)	Multiple trials	Repurposed drug	Anti-virals	Phase III
Favipiravir + Azithromycin	Ministry of Health, Turkey	Repurposed drug	Anti-virals	Phase III
Favipiravir + Nafamostat Mesilate	The University of Tokyo foundation	Repurposed drug	Anti-virals	Phase III
Favipiravir lopinavir /Ritonavir	Rajavithi Hospital	Repurposed drug	Anti-virals	Phase III
Hydroxychloroquine	Multiple trials	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Isoprinosine	Ain Shams University	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Ivermectin + Chloroquine	Tanta University	Repurposed drug	Anti-virals	Phase III
Kineret (ANAKINRA)	University Hospital, Ghent	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Leavmisole + Isoprinosine	Ain Shams University	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Lenzilumab	Humanigen Inc.	Novel	Anti-inflammatory / immunomodulator	Phase III
Levamisole	Ain Shams University	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Lopinavir/ritonavir plus Interferon $\beta$ -1a	Institut National de la Santé Et de la Recherche Médicale, France	Repurposed drug	Anti-virals	Phase III
Naproxen	Assistance Publique - Hôpitaux de Paris	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Nitazoxanide + Azithromycin	Tanta University	Repurposed drug	Anti-virals	Phase III
Nitazoxanide + Ivermectin + Chloroquine	Tanta University	Repurposed drug	Anti-virals	Phase III
Nitazoxanide + Ribavirin + Ivermectin	Mansoura University	Repurposed drug	Anti-virals	Phase III
OM85	The University of Queensland	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Remdesivir + Tocilizumab	Hoffmann-La Roche Gilead Sciences	Repurposed drug	Anti-virals	Phase III
Ritonavir + Lopinavir (Kaletra)	Abbvie Inc.	Repurposed drug	Anti-virals	Phase III
Ritonavir+Oseltamivir	Asclepis Pharma Inc.	Repurposed drug	Anti-virals	Phase III

Ruxolitinib (Jakafi or Jakavi)	Grupo Cooperativo de Hemopatías Malignas Novartis Incyte University of Colorado, Denver	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Sildenafil	Tongji Hospital	Repurposed drug	ARDS	Phase III
Siltuximab	University Hospital, Ghent	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Sofosbuvir + Daclastavir	Digestive Disease Research Institute	Repurposed drug	Anti-virals	Phase III
Symbicort Turbohaler (Budesonide/Formoterol fumarate)	Assistance Publique - Hôpitaux de Paris	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Tocilizumab	Multiple trials	Repurposed drug	Anti-inflammatory / immunomodulator	Phase III
Tradipitant	Vanda Pharmaceuticals	Novel	Anti-inflammatory / immunomodulator	Phase III
Triazavirin	Heilongjiang Province hospital	Novel	Anti-virals	Phase III
Vitamin C	Université de Sherbrooke	Repurposed drug	Dietary supplement	Phase III
Azoximer Bromide	NPO Petrovax	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II/III
Baricitinib (Olumiant or Baricinix)	Eli Lilly and Company Hospital of Prato Nova Scotia Health Authority Dalhousie University	Repurposed drug	Anti-virals	Phase II/III
Convalescent plasma	Multiple trials	Novel	Anti-virals	Phase II/III
Dexamethasone	University of Oxford	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II/III
Escin	University of Catanzaro	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II/III
Favipiravir and chloroquine	Beijing Chao-yang Hospital	Repurposed drug	Anti-virals	Phase II/III
HCQ + LPV/r + Oseltamivir	Tehran University of Medical Sciences	Repurposed drug	Anti-virals	Phase II/III
HCQ + LPV/r + Oseltamivir + Sofosbuvir	Tehran University of Medical Sciences	Repurposed drug	Anti-virals	Phase II/III
HCQ + Nitazoxanide	Tanta University	Repurposed drug	Anti-virals	Phase II/III
IFX-1 (BDB-1)	InflaRx GmbH Beijing Defengrei Biotechnology	Novel	Anti-inflammatory / immunomodulator	Phase II/III
Ivermectin	Tanta University	Repurposed drug	Anti-virals	Phase II/III
Ivermectin + Nitazoxanide	Tanta University	Repurposed drug	Anti-virals	Phase II/III
Lactoferrin	Cairo University	Repurposed drug	Anti-virals	Phase II/III
Methylprednisolone	Multiple	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II/III
Nafamostat	University Hospital Padova	Repurposed drug	Anti-virals	Phase II/III
Niclosamide	Tanta University	Repurposed drug	Anti-virals	Phase II/III
Nitazoxanide	Tanta University	Repurposed drug	Anti-virals	Phase II/III

Remdesivir (GS-5734)+Hydroxychloroquine	Oslo University Hospital	Novel	Anti-virals	Phase II/III
Sarilumab	Multiple trials	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II/III
Acalabrutinib	AstraZeneca	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Alvelestat	Kafrelsheikh University	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Aplidin®(plitidepsin)	PharmaMar	Repurposed drug	Anti-virals	Phase II
AT-527	Atea Pharmaceuticals	Novel	Anti-virals	Phase II
Aviptadil	Neurorx Inc. Relief Therapeutics Holding SA	Novel	Anti-inflammatory / immunomodulator	Phase II
Bevacizumab	Genentech Inc. Roche	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
BLD-2660	Blade Therapeutics	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Chloroquine	Multiple trials	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Clevudine	Bukwang Pharmaceutical	Repurposed drug	Anti-virals	Phase II
CYT107	Revimmune	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Dialyzable leukocyte extract	National Polytechnic Institute, Mexico	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
EIDD-2801	Ridgeback Biotherapeutics LP	Novel	Anti-virals	Phase II
Fingolimod 0.5 mg	First Affiliated Hospital of Fujian Medical University	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
HCQ + Baricitinib	Hospital Universitario de Fuenlabrada	Repurposed drug	Anti-virals	Phase II
HCQ + Imatinib	Hospital Universitario de Fuenlabrada	Repurposed drug	Anti-virals	Phase II
HLCM051	Healios K.K.	Novel	Cell-based therapy	Phase II
Hydroxychloroquine + azithromycin + / - tocilizumab	Burnasyan Federal Medical Biophysical Center	Repurposed drug	Anti-virals	Phase II
IFN-β1a solution for inhalation (SNG001)	Synairgen plc	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Isotretinoin	Kafrelsheikh University	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Ieronlimab (PRO 140)	CytoDyn, Inc.	Novel	Anti-virals	Phase II
Lopinavir + Ritonavir + IFN- β1b	University of Hong Kong Hospital Authority, Hong Kong	Repurposed drug	Anti-virals	Phase II
lopinavir/ritonavir	Multiple trials	Repurposed drug	Anti-virals	Phase II
Losartan	University of Minnesota	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
LY3127804	Eli Lilly	Novel	Anti-inflammatory / immunomodulator	Phase II

Mefloquine	Burnasyan Federal Medical Biophysical Center	Repurposed drug	Anti-virals	Phase II
Mefloquine + azithromycin + / - tocilizumab	Burnasyan Federal Medical Biophysical Center	Repurposed drug	Anti-virals	Phase II
N-acetylcysteine	ShuGuang Hospital	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Nitric Oxide	Multiple trials	Repurposed drug	ARDS	Phase II
PD-1 blocking antibody	Southeast University, China	Novel	Anti-inflammatory / immunomodulator	Phase II
Peginterferon Lambda-1a	Stanford University	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
Piclidenoson	Can-Fite BioPharma Rabin Medical Center	Repurposed drug	Anti-virals	Phase II
Pirfenidone	Tongji Hospital	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
PUL-042 Inhalation Solution	Pulmotect, Inc.	Novel	Anti-virals	Phase II
RBT-9 (Stannous protoporphyrin)	Renibus Therapeutics, Inc.	Novel	Anti-inflammatory / immunomodulator	Phase II
RhACE2 (APN01)	Apeiron Biologics	Novel	Anti-virals	Phase II
Ribavirin + Ritonavir/Lopinavir + Interferon Beta-1B	The University of Hong Kong Hospital Authority, Hong Kong	Repurposed drug	Anti-virals	Phase II
Thalidomide	Celgene Corp.	Repurposed drug	Anti-inflammatory / immunomodulator	Phase II
XRx-101	XORTX Therapeutics Inc.	Novel	Anti-inflammatory / immunomodulator	Phase II
IFN-α + rintatolimod	Roswell Park Cancer Institute	Repurposed drug	Anti-inflammatory / immunomodulator	Phase I/II
Meplazumab	Tang-Du Hospital	Novel	Anti-virals	Phase I/II
Mesenchymal Stem Cells	Multiple trials	Repurposed drug	Cell-based therapy	Phase I/II
NK Cells	Multiple	Repurposed drug	Cell-based therapy	Phase I/II
REGN-COV2 (REGN10933+REGN10987)	Regeneron Pharmaceuticals Inc.	Novel	Anti-virals	Phase I/II
TJ003234	I-Mab Biopharma Co. Ltd.	Novel	Anti-inflammatory / immunomodulator	Phase I/II
alpha one antitrypsin inhalation	Ministry of Health, Saudi Arabia	Repurposed drug	Anti-virals	Phase I
AmnioBoost	Lattice Biologics Ltd.	Novel	Anti-inflammatory / immunomodulator	Phase I
Camostat	University of Aarhus	Repurposed drug	Anti-virals	Phase I
Galidesivir	NIAID BioCryst Pharmaceuticals	Novel	Anti-virals	Phase I
JS016	Junshi Biosciences Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) Eli Lilly	Novel	Anti-virals	Phase I

LY-CoV555	Eli Lilly Ab-Cellera NIAID	Novel	Anti-virals	Phase I
N-803	ImmunityBio, Inc.	Repurposed drug	Anti-inflammatory / immunomodulator	Phase I
Recombinant human interferon	Tongji Hospital Shanghai Jiao Tong University School of Medicine Second Affiliated Hospital of Wenzhou Medical University WanBangDe Pharmaceutical Group Co.,Ltd.	Repurposed drug	Anti-inflammatory / immunomodulator	Phase I
TAK-981	Millennium Pharmaceuticals, Inc.	Repurposed drug	Anti-inflammatory / immunomodulator	Phase I
TY027	Tychan Pte. Ltd.	Novel	Anti-virals	Phase I
Ulinastatin	Shanghai Changzheng Hospital	Repurposed drug	Anti-inflammatory / immunomodulator	Phase I
V-SARS inactivated plasma	Immunitor Inc	Novel	Anti-virals	Phase I
Remdesivir (GS-5734)	NIAID Gilead Sciences, Inc.	Novel	Anti-virals	Emergency use authorisation
ASC09F/ritonavir	Ascleptis Pharmaceuticals Co., Ltd. First Affiliated Hospital of Zhejiang University	Anti-virals	Repurposed drug	Unspecified
Azvadine	HeNan Sincere Biotech Co., Ltd	Repurposed drug	Anti-virals	Unspecified
Baloxavir+current antiviral treatment	The First Hospital Affiliated to Zhejiang University's Medical School	Repurposed drug	Anti-virals	Unspecified
Favipiravir + alpha-Interferon atomization	The Third People's Hospital of Shenzhen	Repurposed drug	Anti-virals	Unspecified
Favipiravir and Hydroxychloroquine	King Abdullah International Medical Research Center	Repurposed drug	Anti-virals	Unspecified
Gimsilumab	Roivant Sciences Ltd. Temple University Hospital	Novel	Anti-inflammatory / immunomodulator	Unspecified
Hyperimmune globulin	Grifols SA	Novel	Anti-virals	Unspecified
Lopinavir/litonavir (LPV/r)+ emtricitabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF)	Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital	Repurposed drug	Anti-virals	Unspecified
lopinavir/ritonavir (LPV/r) based regimens	Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital	Repurposed drug	Anti-virals	Unspecified
Lopinavir/ritonavir combined + thymosin	Zhongnan Hospital of Wuhan University	Repurposed drug	Anti-virals	Unspecified
Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection	The 5th Medical Center Chinese PLA General Hospital	Repurposed drug	Anti-virals	Unspecified
Ribavirin + Abidol	Foshan First People's Hospital	Repurposed drug	Anti-virals	Unspecified
2'-O-methyl UTP	Columbia University University of Wisconsin-Madison	Novel	Anti-virals	Pre-clinical
3'-O-methyl UTP	Columbia University University of Wisconsin-Madison	Novel	Anti-virals	Pre-clinical
4A10	Nanjing Medical University	Novel	Anti-virals	Pre-clinical
4A12	Nanjing Medical University	Novel	Anti-virals	Pre-clinical

4A3	Nanjing Medical University	Novel	Anti-virals	Pre-clinical
4D5	Nanjing Medical University	Novel	Anti-virals	Pre-clinical
4E2RCat	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
AB001	Agastiya Biotech	Novel	Anti-virals	Pre-clinical
ABBV-744	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
AC1MTT7T	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
AC-55541	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
ACE-MAB	Mabpharm Ltd. Sorrento Therapeutics Inc.	Novel	Anti-virals	Pre-clinical
ALT-100	Aqualung Therapeutics Corporation	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
Ampligen	Aim Immunotech Inc. GP Pharma SA Goethe University Frankfurt National Institute of Infectious Diseases in Japan	Repurposed drug	Anti-virals	Pre-clinical
Anti-Corona (COVID-19) polyclonal immunoglobulin	Kamada	Novel	Anti-virals	Pre-clinical
Antiviral Fc-Conjugates (AVCs)	Cidara Therapeutics	Novel	Anti-virals	Pre-clinical
Apicidin	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
AT-100 (rhSP-D)	Airway Therapeutics, Inc.,	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
AVA-Trap	Avalon GloboCare	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
AZ3451	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
AZ8838	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
AZD0156	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
Bafilomycin A1	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
B-Cell Select™ platform-based antibody	ImmunoPrecise Antibodies Ltd	Novel	Anti-virals	Pre-clinical
Biotin-16-dUTP	Columbia University University of Wisconsin-Madison	Novel	Anti-virals	Pre-clinical
Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MS-C)	Nantkwest	Novel	Cell-based therapy	Pre-clinical
BPI-002	BeyondSpring	Novel	Anti-inflammatory / immunomodulator	Pre-clinical

BRIL-196	Tsinghua University 3rd People's Hospital of Shenzhen Brii Biosciences	Novel	Anti-virals	Pre-clinical
BRIL-198	Tsinghua University 3rd People's Hospital of Shenzhen Brii Biosciences	Novel	Anti-virals	Pre-clinical
BXT-10	BioXyTran Inc.	Novel	Anti-virals	Pre-clinical
Calcimycin	Institut Pasteur Korea	Repurposed drug	Anti-virals	Pre-clinical
CCT 365623	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Chalcone	Qingdao University	Repurposed drug	Anti-virals	Pre-clinical
CHEMBL1568820	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
CHEMBL3752642	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
Cidofovir diphosphate	Columbia University University of Wisconsin-Madison	Repurposed drug	Anti-virals	Pre-clinical
Cinanserin	Qingdao University	Repurposed drug	Anti-virals	Pre-clinical
CLBS119	Caladrius Biosciences	Novel	Cell-based therapy	Pre-clinical
Compound 10	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Compound 2	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Coronzot	Silkim Pharma Ltd.	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
COV2-2196 and COV2-2130	Vanderbilt University Ology Bioservices Inc. Twist Bioscience Corp. AstraZeneca University of Maryland School of Medicine USAMRIID University of North Carolina at Chapel Hill Washington University School of Medicine, St. Louis	Novel	Anti-virals	Pre-clinical
COV-ENT-1	Enterin	Novel	Anti-virals	Pre-clinical
COVI-Cell™	Sorrento Therapeutics Inc.	Novel	Anti-virals	Pre-clinical
COVID-EIG	Emergent Biosolutions Inc.	Novel	Anti-virals	Pre-clinical
COVID-HIG	Emergent Biosolutions Inc.	Novel	Anti-virals	Pre-clinical
COVI-MAB™	Sorrento Therapeutics Inc.	Novel	Anti-virals	Pre-clinical
COVI-SHIELD™	Sorrento Therapeutics Inc. Mount Sinai Health System	Novel	Anti-virals	Pre-clinical
CP-1	University of Basel	Novel	Anti-virals	Pre-clinical
CP-10	University of Basel	Novel	Anti-virals	Pre-clinical
CP-11	University of Basel	Novel	Anti-virals	Pre-clinical



CP-2	University of Basel	Novel	Anti-virals	Pre-clinical
CP-3	University of Basel	Novel	Anti-virals	Pre-clinical
CP-4	University of Basel	Novel	Anti-virals	Pre-clinical
CP-5	University of Basel	Novel	Anti-virals	Pre-clinical
CP-6	University of Basel	Novel	Anti-virals	Pre-clinical
CP-7	University of Basel	Novel	Anti-virals	Pre-clinical
CP-8	University of Basel	Novel	Anti-virals	Pre-clinical
CP-9	University of Basel	Novel	Anti-virals	Pre-clinical
CPI-0610	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
CR3022	University of Oxford The Rosalind Franklin Institute Protein Production UK Public Health England Diamond Light Source Ltd Mahidol University Instruct-ERIC	Novel	Anti-virals	Pre-clinical
CT-P59	Celltrion Korea Centers for Disease Control and Prevention (KCDC)	Novel	Anti-virals	Pre-clinical
CV-15 (iCP-NI)	Celliverty Therapeutics	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
Cycloheximide	Institut Pasteur Korea	Repurposed drug	Anti-virals	Pre-clinical
Cynarine	SOM Biotech Ewha Woman's University	Repurposed drug	Anti-virals	Pre-clinical
DARPin® therapeutics	Molecular Partners AG Spiez Laboratory	Novel	Anti-virals	Pre-clinical
DBET6	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Decylphosphinate	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
Deoxyrhapontin	Qingdao University	Repurposed drug	Anti-virals	Pre-clinical
DIBI	Chelation Partners	Novel	Other	Pre-clinical
Digitoxigenin	Institut Pasteur Korea	Repurposed drug	Anti-virals	Pre-clinical
E-52862	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Ebselen	Qingdao University	Repurposed drug	Anti-virals	Pre-clinical
Enzaplatovir	Qingdao University	Repurposed drug	Anti-virals	Pre-clinical
Eravacycline	SOM Biotech Ewha Woman's University	Repurposed drug	Anti-virals	Pre-clinical
Fully human IgG1 mAb (47D11)	Harbour Biomed Erasmus MC	Novel	Anti-virals	Pre-clinical

	Utrecht University Mount Sinai Health System			
Fully human IgG1 mAbs targeting multiple undisclosed epitopes (polytope) on SARS-CoV-2	ImmunoPrecise Antibodies	Novel	Anti-virals	Pre-clinical
GB110	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
GC373	University of Alberta	Novel	Anti-virals	Pre-clinical
GC376	University of Alberta	Novel	Anti-virals	Pre-clinical
Genz-123346	Israel Institute for Biological Research	Repurposed drug	Anti-virals	Pre-clinical
GENZ-667161	Israel Institute for Biological Research	Repurposed drug	Anti-virals	Pre-clinical
GTB-3550	GT Biopharma, Inc.	Novel	Anti-virals	Pre-clinical
H-89	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Hycanthon	US NIH	Repurposed drug	Anti-virals	Pre-clinical
IDX-184	University of Al-Jouf	Repurposed drug	Anti-virals	Pre-clinical
IHVR-19029	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
JQ1	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
KL4 surfactant	Windtree Therapeutics, Inc	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
Lanatoside C	Institut Pasteur Korea	Repurposed drug	Anti-virals	Pre-clinical
LEAPS peptides	CEL-SCI University of Georgia Center for Vaccines and Immunology	Novel	Anti-virals	Pre-clinical
Merimepodib	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
MesenCure	Bonus Biogroup	Novel	Cell-based therapy	Pre-clinical
MI-1851	Philipps-University, Marburg	Repurposed drug	Anti-virals	Pre-clinical
MI-1900	Philipps-University, Marburg	Repurposed drug	Anti-virals	Pre-clinical
MI-432	Philipps-University, Marburg	Repurposed drug	Anti-virals	Pre-clinical
MK-2206	Charité-Universitätsmedizin Berlin	Repurposed drug	Anti-virals	Pre-clinical
MZ1	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Neumifil™	Pneumagen	Novel	Anti-virals	Pre-clinical
N-Nonyl Deoxynojirimycin	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
Noscapine	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
NoveCite Cells (NC-MSCs)	Novellus Citius	Novel	Cell-based therapy	Pre-clinical
NP-120 (ifenprodil)	Algernon Pharmaceuticals	Repurposed drug	Anti-virals	Pre-clinical
OT-101 (Trabedersen)	Oncotelic Inc	Novel	Anti-virals	Pre-clinical

Oteseconazole	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
PB28	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
PBDNJ0803	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
PD-144418	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Pevonedistat	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Prexasertib	SOM Biotech Ewha Woman's University	Repurposed drug	Anti-virals	Pre-clinical
Pritumumab	Nascent Biotech Inc.	Novel	Anti-virals	Pre-clinical
PS3061	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
PX-12	Shanghaitech University	Repurposed drug	Anti-virals	Pre-clinical
rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin)	GigaGen	Novel	Anti-virals	Pre-clinical
Retro-2.1	University of Bern	Repurposed drug	Anti-virals	Pre-clinical
RHB-107 (upamostat, WX-671)	RedHill Biopharma Ltd. NIAID	Novel	Anti-virals	Pre-clinical
RHCDS-13b	German Center for Infection Research (DZIF)	Novel	Anti-virals	Pre-clinical
rIFN alpha14	ILC Therapeutics	Repurposed drug	Anti-virals	Pre-clinical
ROC-325	US NIH	Repurposed drug	Anti-virals	Pre-clinical
RS-PPCC	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
RVX-208	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
SAB-185	SAb Biotherapeutics, Inc.	Novel	Anti-virals	Pre-clinical
Sanglifehrin A	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Sapanisertib	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
SI-F019	SYSTIMMUNE INC.	Novel	Anti-virals	Pre-clinical
siRNA therapeutics	Olix Pharmaceuticals Inc.	Novel	Anti-virals	Pre-clinical
Stavudine triphosphate	Columbia University	Repurposed drug	Anti-virals	Pre-clinical
STI-4398 (COVIDTrap™ protein)	Sorrento Therapeutics Inc.	Novel	Anti-virals	Pre-clinical
TAK-888	Takeda CSL Behring Biotest AG Bio Products Laboratory LFB Octapharma	Novel	Anti-virals	Pre-clinical

TDZD-8	Qingdao University	Repurposed drug	Anti-virals	Pre-clinical
Teicoplanin	Sun Yat-sen University, Guangdong General Hospital and Guangdong Academy of Medical Sciences	Repurposed drug	Anti-virals	Pre-clinical
Ternatin 4	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
TMCB	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Tomivosertib	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
TZLS-501	Tiziana Life Sciences plc	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
TZLS-501	Tiziana Life Sciences plc	Repurposed drug	Anti-inflammatory / immunomodulator	Pre-clinical
Ultra-high affinity mAbs	Distributed Bio	Novel	Anti-virals	Pre-clinical
Unnamed	Cocrystal Pharma	Novel	Anti-virals	Pre-clinical
Unnamed	Kleo Pharmaceuticals Green Cross LabCell	Novel	Anti-inflammatory / immunomodulator	Pre-clinical
Unnamed	Pfizer Inc.	Novel	Anti-virals	Pre-clinical
Unnamed antibody	YUMAB CORAT consortium	Novel	Anti-virals	Pre-clinical
URMC-0990-C	University of Bern	Novel	Anti-virals	Pre-clinical
Verdinexor	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Vicromax™	BioSig Technologies, Inc.	Novel	Anti-virals	Pre-clinical
VIR-7831 and VIR-7832	Vir Biotechnology Inc. Samsung Biologics GSK	Novel	Anti-virals	Pre-clinical
WDB002	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
WP1122	Moleculin Biotech, Inc., University of Texas Medical Branch at Galveston (UTMB)	Novel	Anti-virals	Pre-clinical
XL413	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Z-FA-FMK	University of Michigan	Repurposed drug	Anti-virals	Pre-clinical
ZINC1775962367	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
ZINC4326719	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
ZINC4511851	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical

ZINC95559591	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Zotatifin	QBI COVID-19 Research Group (QCRG) University of California San Francisco	Repurposed drug	Anti-virals	Pre-clinical
Allogeneic, off-the-shelf, virus specific T-cell therapies	AlloVir Baylor College of Medicine	Novel	Anti-virals	Discovery
Antiviral compounds	Cocrystal Pharma Inc.	Novel	Anti-virals	Discovery
Bucillamine	Revive Therapeutics Ltd.	Repurposed drug	Anti-inflammatory / immunomodulator	Discovery
Fully human neutralizing antibodies	Amgen	Novel	Anti-virals	Discovery
Nanobody Therapeutic	Adaptive Biotechnologies	Novel	Anti-virals	Discovery
NI007	BioDuro LLC	Novel	Anti-virals	Discovery
Phosphorodiamidate morpholino oligomer (PMO) platform based therapy	Neurimmune AG Ethris GmbH	Novel	Anti-virals	Discovery
Reactive aldehyde species (RASP) inhibitors (including ADX-629 and reproxalap)	Sarepta Therapeutics, Inc. USAMRIID	Novel	Anti-virals	Discovery
siRNA therapeutics	Aldeyra Therapeutics, Inc.	Novel	Anti-virals	Discovery
siRNA therapeutics	Sirnaomics Inc.	Novel	Anti-virals	Discovery
Unnamed	Ablexis AlivaMab Berkeley Lights	Novel	Anti-virals	Discovery
Unnamed	Cytovia	Novel	Anti-inflammatory / immunomodulator	Discovery
Unnamed	Imperial College London	Novel	Anti-virals	Discovery
Unnamed	Janssen Research & Development, LLC Rega Institute of Medical Research	Novel	Anti-virals	Discovery
Unnamed	Kainos Medicine	Novel	Anti-virals	Discovery
Unnamed	Lion TCR	Novel	Cell-based therapy	Discovery
Unnamed	NanoViricides	Novel	Anti-virals	Discovery
Unnamed	Nuritas	Novel	Anti-virals	Discovery
Unnamed	Q BiomedMannin Research Cyclica	Novel	Other	Discovery
Unnamed antibody	Ghent University University of Texas at Austin German Primate Center – Leibniz Institute for Primate Research	Novel	Anti-virals	Discovery
Unnamed antibody	Institut Pasteur Shanghai Jiangsu Alphamab Biopharmaceuticals Co., Ltd.	Novel	Anti-virals	Discovery
Unnamed antibody	Institut Pasteur Shanghai Jiangsu Alphamab Biopharmaceuticals Co., Ltd.	Novel	Anti-virals	Discovery

Unnamed antibody	Serimmune Inc., Twist Bioscience	Novel	Anti-virals	Discovery
VIR-2703 (ALN-COV)	Alnylam Pharmaceuticals Inc. Vir Biotechnology Inc.	Novel	Anti-virals	Discovery

## Appendix 3 EudraCT registered studies (n=67, July 6<sup>th</sup> 2020)

source: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024262-22/DE>

Table A 3: EudraCT registered Covid19 studies (all)

EudraCT Number	Sponsor Protocol Number	Sponsor Name	Full Title	Start Date	Medical condition	Population Age	Gender	Trial protocol
<u>2020-001331-26</u>	PROLIFIC2020	Cambridge University Hospitals NHS Foundation Trust	ChemoPROphylaxis For covid-19 infeCtious disease (the PROLIFIC trial)	2020-04-14	Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<u>2020-001441-39</u>	VIR20001	University of Oxford	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)	2020-05-12	COVID-19, acute respiratory illness	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing) <u>IT</u> (Ongoing)
<u>2020-001497-30</u>	ALXN1210-COV-305	Alexion Pharmaceuticals, Inc.	COVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19	2020-05-07	COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing) <u>ER</u> (Ongoing) <u>ES</u> (Ongoing)
<u>2020-001565-37</u>	PrEP_COVID	ISGlobal	PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL.	2020-04-03	COVID-19	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<u>2020-001777-71</u>	RAVEN	Guy's and St Thomas' NHS Foundation Trust	Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiEnts - RAVEN	2020-05-06	Severe COVID-19 infection with risk of need for mechanical ventilation.	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<u>2020-001618-39</u>	CL08-ORY-2001_COVID-19	Oryzon Genomics S. A.	A Phase II, randomized, open-label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with	2020-04-24	Acute Respiratory Distress Syndrome (ARDS)	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)

			standard of care treatment to prevent Acute Respiratory Distress...					
<b><u>2020-002110-41</u></b>	CRUKD/20/002	Cancer Research UK	SPIKE-1 TRIAL: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated memb...	2020-06-18	COVID-19	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-002091-12</u></b>	HUVE-19-CT-001	HUVEPHARMA EOOD	Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and man...	2020-05-15	confirmed SARS-CoV-2 infection	Adults, Elderly	Male, Female	<u>BG</u> (Ongoing)
<b><u>2020-001671-32</u></b>	STS-BDB001-04	Staidson (Beijing) Biopharmaceutical Co., Ltd. and Beijing Defengrui Biological Technology Co., Ltd.	A multi-center, open-label, randomized parallel controlled evaluation on the efficacy and safety of BDB-001 injection in the treatment of progressive severe COVID-19 in phase II	2020-05-28	COVID-19	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001453-49</u></b>	GS-US-540-5821	Gilead Sciences, Inc.	Expanded Access Treatment Protocol: Remdesivir (RDV;GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection- COVID-19	2020-04-10	Coronavirus disease 2019 (COVID-19)	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001308-40</u></b>	INHIXACOV19	ALMA MATER STUDIORUM UNIVERSITÀ DI BOLOGNA	Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID19: a pilot phase II single-arm study, INHIXACOV19	2020-05-04	Hospitalized adult patients with microbiologically confirmed moderate-severe COVID-19 infection	Adults, Elderly	Male, Female	<u>IT</u> (Ongoing)
<b><u>2020-001640-26</u></b>	132151	University College London	A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA) in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial	2020-04-17	Acute respiratory distress syndrome (ARDS) caused by COVID-19	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-001904-41</u></b>	GETAFIX-2020	NHS Greater Glasgow and Clyde	Glasgow Early Treatment Arm Favipiravir : A randomized controlled study of favipiravir as	2020-05-20	COVID-19	Adolescents, Under 18, Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)



			an early treatment arm in COVID-19 hospitalized patients					
<b><u>2020-001445-39</u></b>	TACRO-BELL-COVID	Dr. Xavier Solanich Moreno. Servei Medicina Interna. Hospital de Bellvitge	PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVI...	2020-03-31	Hospitalized patients with severe pneumonia secondary to COVID-19	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001243-15</u></b>	S63874	UZLeuven	Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.	2020-03-26	COVID-19	Adults, Elderly	Male, Female	<u>BE</u> (Completed)
<b><u>2020-001469-35</u></b>	QUARANTINE2 020	Wroclaw Medical University	A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for ...	2020-04-08	COVID-19 (Coronavirus Disease 2019)	Adults, Elderly	Male, Female	<u>PL</u> (Ongoing)
<b><u>2020-001823-15</u></b>	20CH089	CHU de Saint Etienne	Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study	2020-04-28	covid-19	Adults, Elderly	Male, Female	<u>FR</u> (Ongoing)
<b><u>2020-001335-28</u></b>	IFX-1-P.2.9	InflaRx GmbH	A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - "PANAMO	2020-03-29	Severe pneumonia in context of COVID-19	Adults, Elderly	Male, Female	<u>NL</u> (Ongoing) <u>DE</u> (Ongoing))
<b><u>2020-001457-43</u></b>	APHP200388	APHP	Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia	2020-04-10	acute hypoxemic respiratory failure (AHRF)	Adults, Elderly	Male, Female	<u>FR</u> (Ongoing)
<b><u>2020-001474-29</u></b>	SAINT	Clínica Universidad de Navarra/Universidad de Navarra	Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission	2020-05-07	COVID-19	Adults	Male, Female	<u>ES</u> (Ongoing)

<b><u>2020-001606-33</u></b>	HIACO-19	Instituto Investigación Sanitario Biocruces Bizkaia	Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection.	2020-04-07	COVID-19 infection	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001052-18</u></b>	10	Regents of the University of Minnesota	A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U...	2020-03-25	Influenza COVID-19	Adults, Elderly	Male, Female	<u>DK</u> (Ongoing) <u>GB</u> (Ongoing) <u>GR</u> (Ongoing) <u>ES</u> (Ongoing)
<b><u>2020-001236-10</u></b>	COVID-19	Amsterdam UMC	COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19 – a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease	2020-03-31	Medical condition: Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease.	Adults, Elderly	Male, Female	<u>NL</u> (Ongoing)
<b><u>2020-001960-28</u></b>	RCTVITD/SARS-CoV-19	Investigation Institute Bioaraba	Efficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19)	2020-05-25	COVID-19 infection	Adults	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001849-39</u></b>	NETs-C19	Region Skåne	Aerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trial	2020-05-18	SARS-coronavirus-2 infection	Adults, Elderly	Male, Female	<u>SE</u> (Ongoing)
<b><u>2020-002035-30</u></b>	TOFACOV-2	AZIENDA OSPEDALIERO-UNIVERSITARIA OSPEDALI RIUNITI DI ANCONA	TOFACitinib plus Hydroxycloquine vs Hydroxycloquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial	2020-05-15	SARS-CoV2 related Interstitial Pneumonia	Adults	Male, Female	<u>IT</u> (Ongoing)
<b><u>2020-001636-95</u></b>	282110	University of Manchester	Subcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility & Pharmacokinetics/ Pharmacodynamics study	2020-05-20	Suspected or confirmed SARS-CoV-2 infection (confirmed by RNA-PCR)	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)

<b><u>2020-001493-29</u></b>	CVC-for-COVID-19	Charité - Universitätsmedizin Berlin	Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients	2020-05-11	SARS-CoV-2 infection	Adults	Male, Female	<u>DE</u> (Ongoing)
<b><u>2020-000842-32</u></b>	GS-US-540-5774	Gilead Sciences, Inc.	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment	2020-03-18	Coronavirus disease 2019 (COVID-19)	Adolescents, Under 18, Adults, Elderly	Male, Female	<u>DE</u> (Ongoing) <u>ES</u> (Ongoing) <u>FR</u> (Ongoing) <u>IT</u> (Ongoing) <u>NL</u> (Ongoing) <u>GB</u> (Ongoing) <u>SE</u> (Completed)
<b><u>2020-002230-32</u></b>		University of Edinburgh	Rapid Experimental Medicine for COVID-19	2020-06-23	COVID-19	Under 18, Adults	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-001023-14</u></b>	SG016	Synairgen Research Limited	A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infectio...	2020-03-17	COVID-19	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-002229-27</u></b>	TACTIC-E	Cambridge University Hospitals NHS Foundation Trust	multi-Arm Therapeutic study in pre-ICU patients admitted with Covid-19 – Experimental drugs and mechanisms	2020-06-09	SARS-Cov-2	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-002060-31</u></b>	WHOCovid-19coreprotocol	Masaryk University	An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care	2020-06-22	COVID-19	Adults, Elderly	Male, Female	<u>CZ</u> (Ongoing)
<b><u>2020-001786-36</u></b>	ILIAD-7-UK-Cohort	RevImmune SAS France	Recombinant Interleukin-7 (CYT107) to Improve clinical outcomes in lymphopenic patients with COVID-19 infection "ILIAD 7 trial"	2020-05-06	Lymphopenia and T cell exhaustion in COVID-19 patients	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-000841-15</u></b>	GS-US-540-5773	Gilead Sciences, Inc.	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19	2020-03-18	Coronavirus disease 2019 (COVID-19)	Adolescents, Under 18, Adults, Elderly	Male, Female	<u>DE</u> (Ongoing) <u>ES</u> (Ongoing) <u>FR</u> (Ongoing) <u>IT</u> (Ongoing) <u>NL</u> (Ongoing) <u>GB</u> (Ongoing) <u>SE</u> (Completed)

<b><u>2020-001188-96</u></b>	20PH061	CHU de Saint Etienne	Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial	2020-04-07	Healthcare workers	Adults	Male, Female	<u>FR</u> (Ongoing)
<b><u>2020-001860-27</u></b>	UoL001542	University of Liverpool	AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment	2020-05-12	Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2)	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-001264-28</u></b>	P2-IMU-838-COV	Immunic AG	A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Ca...	2020-05-28	COVID-19	Adults, Elderly	Male, Female	<u>DE</u> (Ongoing) <u>BG</u> (Ongoing) <u>GR</u> (Ongoing) <u>HU</u> (Ongoing)
<b><u>2020-001598-66</u></b>	P20/06	Centre Hospitalier de Versailles	Preliminary randomized controlled trial of poractant alfa (Curosurf®) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 ...	2020-05-04	Acute respiratory distress syndrome due to COVID-19 viral pneumonia	Adults, Elderly	Male, Female	<u>FR</u> (Ongoing)
<b><u>2020-001512-26</u></b>	COMIHY	Universitätsklinikum Tübingen	Hydroxychloroquine for the treatment of mild COVID-19 disease	2020-04-22	Acute coronavirus disease 2019	Adults, Elderly	Male, Female	<u>DE</u> (Restarted)
<b><u>2020-001364-29</u></b>	AdiQure/COVID-19	Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud	Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia	2020-04-20	Severe COVID-19 pneumonia	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001972-13</u></b>	COVID-19HD	AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA	Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requir...	2020-05-21	Hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation.	Adults, Elderly	Male, Female	<u>IT</u> (Ongoing)
<b><u>2020-001614-38</u></b>	S63935	UZLeuven	Covid-19: A randomized, open-label, adaptive, proof-of- concept	2020-04-22	COVID-19	Adults, Elderly	Male, Female	<u>BE</u> (Ongoing)

			clinical trial of new antiviral drug candidates against SARS-CoV-2.					
<b><u>2020-001450-22</u></b>	MESCEL-COVID19	Fundación de Investigación del Hospital Infantil Universitario Niño Jesús	Phase II Clinical Trial to explore the efficacy of allogeneic mesenchymal cells from umbilical cord tissue in patients with severe pulmonary involvement by COVID-19.	2020-04-29	Severe pulmonary involvement by COVID-19	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001113-21</u></b>	NDPHRECOVERY	University of Oxford	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	2020-03-17	COVID-19 (infection with SARS-CoV-2 virus)	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-001031-27</u></b>	CQ4COV19	FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA	Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)	2020-03-14	SARS-CoV-2 Respiratory Viral Infection	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2019-002688-89</u></b>	ALICELL-CT-01	Histocell S.L.	Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived...	2019-12-10	acute respiratory distress syndrome	Adults	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001531-27</u></b>	SARICOR	Fundación para la Investigación Biomédica de Córdoba	Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome	2020-04-18	SARS-CoV-2 infection causing respiratory disease and cytokine release syndrome	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001244-26</u></b>	COV-2-SOLNATIDE-20	Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria	COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.	2020-04-11	Pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS	Adults, Elderly	Male, Female	<u>AT</u> (Ongoing)
<b><u>2020-001390-76</u></b>	ESCAPE	ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"	A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patie...	2020-04-27	Covid-19 coronavirus infection	Adults, Elderly	Male, Female	<u>IT</u> (Ongoing)

<b><u>2020-001795-15</u></b>	COMBAT-19	OSPEDALE SAN RAFFAELE	A randomized, double blind, placebo-Controlled trial of Mavrilimumab for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation: the COMBAT-19 trial	2020-05-07	Respiratory failure during COVID-19 pneumonia and hyperinflammation	Adults, Elderly	Male, Female	<u>IT</u> (Ongoing)
<b><u>2020-001302-30</u></b>	ACOVACT	Medical University of Vienna	A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute re...	2020-04-15	Infection with SARS-COV-2 (=COVID-19)	Adults, Elderly	Male, Female	<u>AT</u> (Ongoing)
<b><u>2020-001203-16</u></b>	LIBERATE	Guy's and St Thomas' NHS Foundation Trust	Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial	2020-05-06	COVID-19; respiratory failure; hypoxaemia.	Adults, Elderly	Male, Female	<u>GB</u> (Ongoing)
<b><u>2020-001198-55</u></b>	KronLungesyg_COVID_19_protokol_2	Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)	Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID	2020-04-03	This trial will investigate infection with coronavirus (COVID-19) in patients who are admitted to hospital	Adults, Elderly	Male, Female	<u>DK</u> (Ongoing)
<b><u>2020-001573-78</u></b>	87RI20_0012	RevImmune	Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection	2020-05-06	SARSCo-V-2	Adults, Elderly	Male, Female	<u>FR</u> (Ongoing)
<b><u>2020-001739-28</u></b>	S63979	UZLeuven	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19.	2020-05-20	COVID-19	Adults, Elderly	Male, Female	<u>BE</u> (Ongoing)
<b><u>2020-001435-27</u></b>	CHUBX2020/12	CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC	Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treat...	2020-04-10	severe acute respiratory syndrome coronavirus 2(SARS-CoV 2)	Elderly	Male, Female	<u>FR</u> (Ongoing)

<b><u>2020-002287-31</u></b>	PREVICHARM	FIMABIS	Prevention of COVID19 infection with hydroxychloroquine in institutionalized older people and nursing home staff. An open, randomized controlled stepped-wedge clinical trial by clusters. PREVICHARM...	2020-05-22	COVID-19	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing)
<b><u>2020-001039-29</u></b>	ESCAPE	HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS	EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL	2020-04-01	Organ dysfunction by the novel SARS-Cov-2 virus	Adults, Elderly	Male, Female	<u>GR</u> (Ongoing)
<b><u>2019-004369-42</u></b>	FKS456-001	Fresenius Kabi SwissBioSim GmbH	A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union approved RoActemra® in Patients w...	2020-04-27	Moderately to severely active Rheumatoid Arthritis	Adults, Elderly	Male, Female	<u>HU</u> (Ongoing) <u>SK</u> (Ongoing))
<b><u>2016-004676-22</u></b>	M16-066	AbbVie Deutschland GmbH & Co. KG	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who ...	2019-01-14	Ulcerative Colitis	Adolescents, Under 18, Adults, Elderly	Male, Female	<u>BE</u> (Ongoing) <u>SK</u> (Ongoing) <u>AT</u> (Ongoing) <u>ES</u> (Ongoing) <u>SE</u> (Ongoing) <u>NL</u> (Ongoing) <u>DK</u> (Ongoing) <u>GR</u> (Ongoing) <u>PL</u> (Ongoing) <u>DE</u> (Ongoing) <u>LT</u> (Ongoing) <u>PT</u> (Ongoing) <u>GB</u> (Ongoing) <u>LV</u> (Ongoing) <u>SI</u> (Ongoing) <u>BG</u> (Ongoing) <u>HR</u> (Ongoing)

<b><u>2018-001516-30</u></b>	GDX-44-007	GUERBET	Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopichol, in pediatric patients from 2 to 17 years of age undergoing contrast-enhanced MRI.	Information not available in EudraCT	Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System	Children, Adolescents, Under 18	Male, Female	<u>SK</u> (Ongoing) <u>PL</u> (Ongoing) <u>BG</u> (Ongoing)
<b><u>2017-001365-24</u></b>	WN39658	Roche Farma S.A.(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F.Hoffmann-La Roche LTD	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE	2018-06-05	Alzheimer's Disease (AD)	Adults, Elderly	Male, Female	<u>ES</u> (Ongoing) <u>GB</u> (Ongoing) <u>DK</u> (Ongoing) <u>BE</u> (Ongoing) <u>PT</u> (Ongoing) <u>PL</u> (Ongoing) <u>NL</u> (Ongoing) <u>SE</u> (Ongoing) <u>FI</u> (Ongoing) <u>HR</u> (Ongoing)
<b><u>2015-002340-14</u></b>	REMAP-CAP	University Medical Center Utrecht	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19	2015-09-16	Severe Community Acquired Pneumonia	Adults, Elderly	Male, Female	<u>NL</u> (Ongoing) <u>IE</u> (Ongoing) <u>PT</u> (Ongoing) <u>GB</u> (Ongoing) <u>HU</u> (Ongoing) <u>BE</u> (Ongoing) <u>DE</u> (Ongoing) <u>HR</u> (Ongoing) <u>ES</u> (Ongoing) <u>FR</u> (Ongoing) <u>FI</u> (Ongoing)
<b><u>2016-003191-50</u></b>	M16-000	AbbVie Deutschland GmbH & Co. KG	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Res...	2017-08-23	Crohn's disease	Adolescents, Under 18, Adults, Elderly	Male, Female	<u>SK</u> (Ongoing) <u>DK</u> (Ongoing) <u>DE</u> (Ongoing) <u>PT</u> (Ongoing) <u>CZ</u> (Ongoing) <u>GB</u> (Ongoing) <u>LV</u> (Ongoing) <u>IE</u> (Ongoing) <u>BG</u> (Ongoing) <u>AT</u> (Ongoing) <u>PL</u> (Ongoing) <u>NL</u> (Ongoing)



								EE (Ongoing) SE (Ongoing) ES (Ongoing) GR (Ongoing) NO (Ongoing) LT (Ongoing) BE (Ongoing) HR (Ongoing) FR (Ongoing)
<b><u>2017-001364-38</u></b>	WN29922	Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche LTD	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE	2018-06-18	Alzheimer's Disease (AD)	Adults, Elderly	Male, Female	ES (Ongoing) BE (Completed) LT (Ongoing) DE (Ongoing) HU (Ongoing) DK (Completed)
<b><u>2016-000674-38</u></b>	M14-533	AbbVie Deutschland GmbH & Co. KG	A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)	2016-09-20	Ulcerative Colitis	Adolescents, Under 18, Adults, Elderly	Male, Female	SK (Ongoing) NL (Ongoing) CZ (Ongoing) AT (Ongoing) FI (Ongoing) PL (Ongoing) SE (Completed) GB (Ongoing) DE (Ongoing) LV (Ongoing) GR (Ongoing) EE (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) LT (Ongoing) BE (Ongoing) NO (Ongoing) ES (Ongoing) HR (Ongoing)





**HTA Austria**

Austrian Institute for  
Health Technology Assessment  
GmbH